Metoprolol
- Generic Name
- Metoprolol
- Brand Names
- Kapspargo, Lopressor, Lopressor Hct, Toprol
- Drug Type
- Small Molecule
- Chemical Formula
- C15H25NO3
- CAS Number
- 51384-51-1
- Unique Ingredient Identifier
- GEB06NHM23
- Background
Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release. The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative. To this date, it is one of the preferre...
- Indication
Metoprolol is indicated for the treatment of angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension.
Some off-label uses of metoprolol include supraventricular tachycardia and thyroid storm.
...
- Associated Conditions
- Angina Pectoris, Atrial Fibrillation, Hypertension, Migraine, Myocardial Infarction, Supraventricular Tachycardia (SVT), Thyroid Crisis, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III)
- Associated Therapies
- -
Effect of Metoprolol on Thalassemia Cardiomyopathy
- First Posted Date
- 2013-05-27
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Shiraz University of Medical Sciences
- Target Recruit Count
- 45
- Registration Number
- NCT01863173
- Locations
- 🇮🇷
Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of
Repeated Dose Study for the Investigation of Heritability of and Genetic Influences on Drug Pharmacokinetics
- Conditions
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2014-04-21
- Target Recruit Count
- 117
- Registration Number
- NCT01845194
- Locations
- 🇩🇪
Dept. of Clinical Pharmacology, Georg-August-University of Goettingen, Goettingen, Germany
Risk Factor Control Before Orthopedic Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-04-22
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 198
- Registration Number
- NCT01837069
- Locations
- 🇺🇸
NYU Hospital for Joint Diseases, New York, New York, United States
Economic Impact of Switching From Metoprolol to Nebivolol for Hypertension Treatment
- Conditions
- Interventions
- First Posted Date
- 2013-01-01
- Last Posted Date
- 2013-01-01
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 3000
- Registration Number
- NCT01758263
- Locations
- 🇺🇸
Forest Investigative Site 0, Jersey City, New Jersey, United States
Study to Evaluate the Effect of Eliglustat on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adults
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 14
- Registration Number
- NCT01659944
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
- Conditions
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 17
- Registration Number
- NCT01658657
- Locations
- 🇺🇸
UNC Chapel Hill, Chapel Hill, North Carolina, United States
Rate Control in Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT01655303
- Locations
- 🇮🇷
Rasoul-e-Akram Hospital, Tehran, Iran, Islamic Republic of
Carvedilol for Prevention of Paroxysmal Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 300
- Registration Number
- NCT01608893
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)
- Conditions
- Interventions
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- University of Colorado, Boulder
- Target Recruit Count
- 44
- Registration Number
- NCT01595516
- Locations
- 🇺🇸
UC-Boulder Clinical and Translational Research Center, Boulder, Colorado, United States
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
- Conditions
- Interventions
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT01585623
- Locations
- 🇺🇸
Investigational Site Number 840004, Augusta, Georgia, United States
🇺🇸Investigational Site Number 840002, Philadelphia, Pennsylvania, United States
🇺🇸Investigational Site Number 840001, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.